These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29765219)

  • 1. Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden - a longitudinal population-based register study.
    Polyzoi M; Ahnemark E; Medin E; Ginsberg Y
    Neuropsychiatr Dis Treat; 2018; 14():1149-1161. PubMed ID: 29765219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, Patient Characteristics, and Pharmacological Treatment of Children, Adolescents, and Adults Diagnosed With ADHD in Sweden.
    Giacobini M; Medin E; Ahnemark E; Russo LJ; Carlqvist P
    J Atten Disord; 2018 Jan; 22(1):3-13. PubMed ID: 25376193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of attention-deficit/hyperactivity disorder medication among older adults in Denmark.
    Ormhøj SS; Pottegård A; Gasse C; Rasmussen L
    Br J Clin Pharmacol; 2018 Jul; 84(7):1505-1513. PubMed ID: 29493809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nationwide rate of attention-deficit hyperactivity disorder diagnosis and pharmacotherapy in Korea in 2008-2011.
    Hong M; Kwack YS; Joung YS; Lee SI; Kim B; Sohn SH; Chung US; Yang J; Bhang SY; Hwang JW; Choi HY; Oh IH; Lee YJ; Bahn GH
    Asia Pac Psychiatry; 2014 Dec; 6(4):379-85. PubMed ID: 25277653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare utilization and costs of psychiatric and somatic comorbidities associated with newly diagnosed adult ADHD.
    Garcia-Argibay M; Pandya E; Ahnemark E; Werner-Kiechle T; Andersson LM; Larsson H; Du Rietz E
    Acta Psychiatr Scand; 2021 Jul; 144(1):50-59. PubMed ID: 33749845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register.
    Zhang L; Lagerberg T; Chen Q; Ghirardi L; D'Onofrio BM; Larsson H; Viktorin A; Chang Z
    Evid Based Ment Health; 2021 Nov; 24(4):146-152. PubMed ID: 33795353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in adult psychiatry. A 20-year register study.
    Nylander L; Holmqvist M; Gustafson L; Gillberg C
    Nord J Psychiatry; 2013 Oct; 67(5):344-50. PubMed ID: 23234539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of sleep disorder diagnoses and sleep medication prescriptions in individuals with ADHD across the lifespan: a Swedish nationwide register-based study.
    Ahlberg R; Garcia-Argibay M; Taylor M; Lichtenstein P; D'Onofrio BM; Butwicka A; Hill C; Cortese S; Larsson H; Du Rietz E
    BMJ Ment Health; 2023 Aug; 26(1):. PubMed ID: 37657817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: A population-based cross-sectional study.
    Chen Q; Hartman CA; Haavik J; Harro J; Klungsøyr K; Hegvik TA; Wanders R; Ottosen C; Dalsgaard S; Faraone SV; Larsson H
    PLoS One; 2018; 13(9):e0204516. PubMed ID: 30256837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD: The CAT Study.
    Piñeiro-Dieguez B; Balanzá-Martínez V; García-García P; Soler-López B;
    J Atten Disord; 2016 Dec; 20(12):1066-1075. PubMed ID: 24464326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011.
    Song I; Shin JY
    Epidemiol Health; 2016; 38():e2016045. PubMed ID: 27866408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of sociodemographic and clinical factors in the initiation and discontinuation of attention deficit hyperactivity disorder medication among young adults in Sweden.
    Gémes K; Taipale H; Björkenstam E; Rahman S; Gustafsson K; Tanskanen A; Ekselius L; Mittendorfer-Rutz E; Helgesson M
    Front Psychiatry; 2023; 14():1152286. PubMed ID: 37168083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment.
    Benkert D; Krause KH; Wasem J; Aidelsburger P
    GMS Health Technol Assess; 2010 Sep; 6():Doc13. PubMed ID: 21289886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADHD in Germany: Trends in Diagnosis and Pharmacotherapy.
    Bachmann CJ; Philipsen A; Hoffmann F
    Dtsch Arztebl Int; 2017 Mar; 114(9):141-148. PubMed ID: 28351466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in Antidepressant Use After Initiation of ADHD Medication in Japanese Adults with Comorbid Depression: A Real-World Database Analysis.
    Sakai C; Tsuji T; Nakai T; Namba Y; Mishima H; Fujiwara M; Matsunaga H
    Neuropsychiatr Dis Treat; 2021; 17():3097-3108. PubMed ID: 34675521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort.
    Lemelin M; Boukhris T; Zhao JP; Sheehy O; Bérard A
    Pharmacol Res Perspect; 2021 May; 9(3):e00781. PubMed ID: 34003597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
    Raman SR; Man KKC; Bahmanyar S; Berard A; Bilder S; Boukhris T; Bushnell G; Crystal S; Furu K; KaoYang YH; Karlstad Ø; Kieler H; Kubota K; Lai EC; Martikainen JE; Maura G; Moore N; Montero D; Nakamura H; Neumann A; Pate V; Pottegård A; Pratt NL; Roughead EE; Macias Saint-Gerons D; Stürmer T; Su CC; Zoega H; Sturkenbroom MCJM; Chan EW; Coghill D; Ip P; Wong ICK
    Lancet Psychiatry; 2018 Oct; 5(10):824-835. PubMed ID: 30220514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine.
    Imagawa H; Nagar SP; Montgomery W; Nakamura T; Sato M; Davis KL
    Neuropsychiatr Dis Treat; 2018; 14():611-621. PubMed ID: 29503545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trend, characteristics, and pharmacotherapy of adults diagnosed with attention-deficit/hyperactivity disorder: a nationwide survey in Taiwan.
    Cheng YS; Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Neuropsychiatr Dis Treat; 2017; 13():643-651. PubMed ID: 28280346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.